Shanghai Pulmonary Hospital, Shanghai, China (Global / Institutional) sponsors 62 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 44 active protocols (16 recruiting now), 3 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.